Matarin Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Matarin Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-59,059	Closed	-$549K	–	276
2019 Q2	$549K	Sell	59,059 -22,475	-28%	-$260K	0.04%	230
2019 Q1	$1.13M	Hold	81,534	–	–	0.08%	199
2018 Q4	$890K	Buy	81,534 +5,582	+7%	+$58.9K	0.07%	206
2018 Q3	$960K	Buy	+75,952	New	+$915K	0.06%	219

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Matarin Capital Management's CCXI Position: Q3 2019 in Review

Matarin Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q3 2019, closing a stake of 59,059 shares — an estimated $549K sold.

Matarin Capital Management first reported a position in CCXI in Q3 2018 and held it in 4 quarters. The position peaked at $1.13M in Q1 2019. 100 funds tracked by Wall St. Rank hold CCXI as of Q3 2019.

Matarin Capital Management reported no remaining ChemoCentryx, Inc. position as of Q3 2019 after selling out during the quarter.
Matarin Capital Management sold 59,059 ChemoCentryx, Inc. shares in Q3 2019, an estimated $549K.
Matarin Capital Management first reported a position in ChemoCentryx, Inc. in Q3 2018 and held it in 4 quarters.
Matarin Capital Management's ChemoCentryx, Inc. position peaked at $1.13M in Q1 2019.
100 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2019.

Based on Matarin Capital Management's 13F filing for Q3 2019, filed 5 Nov 2019.